UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

A Community Wellness Program for Adults Living With Long-term Physical Disability

Not Applicable

Completed

Conditions: Physical Disability

Interventions: Behavioral: EnhanceWellness for Disability (EW-D)
Behavioral: Wellness Education

First Posted Date: 2018-08-31

Last Posted Date: 2023-11-21

Lead Sponsor: University of Washington

Target Recruit Count: 516

Registration Number: NCT03653390

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Stage IV Prostate Cancer AJCC v8
Metastatic Malignant Neoplasm in the Bone
Metastatic Prostate Carcinoma
Prostate Adenocarcinoma
Prostate Small Cell Neuroendocrine Carcinoma
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Castration-Sensitive Prostate Carcinoma

Interventions: Drug: Antiandrogen Therapy
Drug: Abiraterone Acetate
Drug: Prednisone
Radiation: Radiation Therapy

First Posted Date: 2018-08-28

Last Posted Date: 2023-10-26

Lead Sponsor: University of Washington

Target Recruit Count: 10

Registration Number: NCT03649841

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Phase 2

Withdrawn

Conditions: HER2/Neu Negative
Recurrent Breast Carcinoma
Estrogen Receptor Negative
Metastatic Breast Cancer
Progesterone Receptor Negative
Triple Negative Breast Cancer

Interventions: Biological: Pembrolizumab
Drug: Cisplatin

First Posted Date: 2018-08-23

Last Posted Date: 2019-04-26

Lead Sponsor: University of Washington

Registration Number: NCT03644589

Locations: 🇺🇸
Seattle Cancer Care Alliance, Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

Not Applicable

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Transitional Cell Carcinoma
Fallopian Tube Undifferentiated Carcinoma
Ovarian Transitional Cell Carcinoma
Fallopian Tube Adenocarcinoma
Fallopian Tube Carcinosarcoma
Fallopian Tube Clear Cell Adenocarcinoma
Ovarian Mucinous Adenocarcinoma
Primary Peritoneal Transitional Cell Carcinoma
Fallopian Tube Serous Adenocarcinoma

Interventions: Other: Exercise Counseling
Other: Aerobic Exercise
Other: Physiological Support
Other: Best Practice
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2018-08-22

Last Posted Date: 2023-11-29

Lead Sponsor: University of Washington

Target Recruit Count: 64

Registration Number: NCT03641287

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Gent for Pharyngeal Gonorrhea (GC)

Phase 2

Terminated

Conditions: Pharyngeal Gonococcal Infection

Interventions: Drug: gentamicin 360mg IM

First Posted Date: 2018-08-15

Last Posted Date: 2020-08-10

Lead Sponsor: University of Washington

Target Recruit Count: 13

Registration Number: NCT03632109

Locations: 🇺🇸
Public Health -- Seattle & King County STD Clinic, Seattle, Washington, United States

Subgroups of Older Adults With Back Pain and Multiple Chronic Conditions

Completed

Conditions: Anxiety
Low Back Pain
Osteoarthritis
Depression

First Posted Date: 2018-08-15

Last Posted Date: 2019-08-19

Lead Sponsor: University of Washington

Target Recruit Count: 8344

Registration Number: NCT03632122

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Non-contrast DWI for Supplemental Screening

Active, not recruiting

Conditions: Breast Cancer

Interventions: Device: Non-contrast MRI
Device: Non-contrast DWI

First Posted Date: 2018-07-31

Last Posted Date: 2025-04-15

Lead Sponsor: University of Washington

Target Recruit Count: 269

Registration Number: NCT03607552

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer

Not Applicable

Terminated

Conditions: Stage IIIA1 Ovarian Cancer AJCC v8
High Grade Ovarian Serous Adenocarcinoma
Stage IIIA Ovarian Cancer AJCC v8
Stage IIIA2 Ovarian Cancer AJCC v8
Stage IIIB Ovarian Cancer AJCC v8
Stage III Ovarian Cancer AJCC v8
Stage IV Ovarian Cancer AJCC v8
Stage IIIC Ovarian Cancer AJCC v8
Stage IVA Ovarian Cancer AJCC v8
Stage IVB Ovarian Cancer AJCC v8

Interventions: Other: Biospecimen Collection
Other: Laboratory Biomarker Analysis
Device: Lavage
Other: Pap Smear

First Posted Date: 2018-07-30

Last Posted Date: 2024-01-17

Lead Sponsor: University of Washington

Target Recruit Count: 52

Registration Number: NCT03606486

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Kenya HIV Self-Testing in PrEP Delivery

Not Applicable

Completed

Conditions: HIV-1-infection

Interventions: Combination Product: 6-month PrEP + blood-based HIV self-test
Combination Product: 6-month PrEP + oral fluid HIV self-test

First Posted Date: 2018-07-20

Last Posted Date: 2024-06-04

Lead Sponsor: University of Washington

Target Recruit Count: 790

Registration Number: NCT03593629

Locations: 🇰🇪
Partners in Health Research and Development - Thika House, Thika, Kenya

Partners PrEP Program

Completed

Conditions: HIV Infections

Interventions: Drug: PrEP
Drug: ART

First Posted Date: 2018-07-13

Last Posted Date: 2021-12-06

Lead Sponsor: University of Washington

Target Recruit Count: 1381

Registration Number: NCT03586128

Locations: 🇺🇬
Makerere University, Kampala, Uganda

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy